Amgen Inc.
AMGNNext catalyst
Anvumetostat
Advanced MTAP-null Solid Tumors
Get an email about AMGN's next catalysts
Track Amgen (AMGN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 26 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline
27 upcoming, 6 past
Anvumetostat Phase 2 Est. Readout
Estimated primary completion for Anvumetostat trial (NCT05094336) in Advanced MTAP-null Solid Tumors. Topline data typically follows completion by weeks to months.
SourceABP 234 Phase 3 Est. Readout (Eucalyptus)
Primary completion for ABP 234 trial (NCT06430866) in Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
SourceBlinatumomab Phase 2 Est. Readout
Estimated primary completion for Blinatumomab trial (NCT03114865) in Acute Lymphoblastic Leukemia. Topline data typically follows completion by weeks to months.
SourceAMG 732 Phase 2 Est. Readout
Primary completion for AMG 732 trial (NCT06401044) in Thyroid Eye Disease
SourcePegfilgrastim Phase 2 Est. Readout
Estimated primary completion for Pegfilgrastim trial (NCT03571633) in HER2-positive Breast Cancer. Topline data typically follows completion by weeks to months.
SourceMaridebart Cafraglutide Phase 3 Est. Readout (MARITIME-1)
Primary completion for Maridebart cafraglutide trial (NCT06858878) in Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
SourceAutologous Stem Cell Transplant (ASCT) Phase 2 Est. Readout (ADVANCE)
Estimated primary completion for Autologous Stem Cell Transplant (ASCT) trial (NCT04268498) in Multiple Myeloma. Topline data typically follows completion by weeks to months.
SourceRomosozumab Prefilled Syringe Phase 2 Est. Readout
Estimated primary completion for Romosozumab Prefilled Syringe trial (NCT04800367) in Premenopausal Idiopathic Osteoporosis. Topline data typically follows completion by weeks to months.
SourceHow AMGN's past catalysts played out
Market Overview
Stock performance and key metrics
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
WebsiteLumakras
Sotorasib
KRAS G12C NSCLC
Cystagon®
Cystinosis
darbepoetin alfa
Anemia
Denosumab (AMG 162)
Postmenopausal Osteoporosis
mFOLFOX6
Gastric Cancer
Zoledronic Acid
Bone Metastases
Denosumab
Osteoporosis
ARM 2
Recurrent and/or Metastatic Head and Neck Cancer
Denosumab (CP2)
Postmenopausal Osteoporosis
Ustekinumab
Psoriasis
Topical treatments or phototherapy
Plaque Psoriasis
Standard Chemotherapy
Cancer
Oxaliplatin Based Chemotherapy
Colorectal Cancer
etanercept pre-filled syringe subcutaneous injection
Rheumatoid Arthritis
Chemotherapy
Gastric Cancer
Teprotumumab
Thyroid Eye Disease
1=Etanercept
Psoriasis
Tarlatamab
Small Cell Lung Cancer
Non-steroidal aromatase inhibitor therapy
Breast Cancer
Recombinant Human Keratinocyte Growth Factor
Stomatitis
Pegloticase
Uncontrolled Gout
Ibuprofen/famotidine
Ulcer
interferon γ-1b
Friedreich's Ataxia
Anakinra (Kineret®)
Rheumatoid Arthritis
Ocrelizumab (US)
Relapsing-remitting Multiple Sclerosis (RRMS)
Aranesp® (darbepoetin alfa)
Kidney Disease
Ibandronate
Postmenopausal Osteoporosis
ABP 710
Arthritis, Rheumatoid
Sotorasib
Non-small Cell Lung Cancer
AMG 386
Ovarian Cancer
AMG 510
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Statin therapy
Coronary Artery Disease (CAD)
Xaluritamig
Metastatic Castration-resistant Prostate Cancer
Darbepoetin alpha
Myelodysplastic Syndrome
filgrastim
Sarcoma
Erenumab Dose 1
Migraine
Etanercept/Autoinjector A
Rheumatoid Arthritis
Cytarabine
Lymphoma
TAC
Breast Cancer
Pegaspargase
Acute Lymphoblastic Leukemia
ABP 654
Plaque Psoriasis
Erenumab Dose 2
Migraine
Denosumab (for the open-label treatment phase)
Cancer
pegfilgrastim
Breast Cancer
Inebilizumab
IgG4 Related Disease
Dazodalibep
Sjögren's Syndrome (SS)
Topical agents
Psoriasis
AMG 162
Postmenopausal Osteoporosis
Cinacalcet HCl
Kidney Disease
ABP 234
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
HPN-100
Cirrhosis
ABP 501
Arthritis, Rheumatoid
Low-intensity chemotherapy regimen
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Palifermin
Head and Neck Cancer
romosozumab HCP administration with PFS
Post-Menopausal Osteoporosis
Olpasiran
Cardiovascular Disease
Cysteamine Bitartrate Delayed-release Capsules
Cystinosis
Romiplostim
Chemotherapy-induced Thrombocytopenia
Darbepoetin alfa and Epoetin alfa
Anemia
AMG 531
Thrombocytopenia
Omitted Vincristine+Dexamethasone pulses
Leukemia, Acute Lymphoblastic
AMG 162/Denosumab
Breast Cancer
Bemarituzumab
Gastric Cancer
Etanercept
Rheumatoid Arthritis
alendronate
Osteoporosis
Erenumab
Migraine
Maridebart cafraglutide
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
ABP 206
Melanoma
Irinotecan Based Chemotherapy
Colorectal Cancer
ABP 692
Relapsing-remitting Multiple Sclerosis (RRMS)
Alendronate Tab
Bone Density
Erenumab Dose 3
Migraine
Atorvastatin
Hyperlipidemia
Carfilzomib
Multiple Myeloma
Aeroquin
Cystic Fibrosis
Omnipaque
Cardiovascular Disease
Commercial Formulation Etanercept
Arthritis, Rheumatoid; Arthritis, Psoriatic
ABP 959
Paroxysmal Nocturnal Hemoglobinuria
Apremilast
Behçet's Disease
Etelcalcetide
Secondary Hyperparathyroidism
Bisphosphonate
Osteogenesis Imperfecta
Ezetimibe
Hyperlipidemia
Evolocumab Pre-filled Syringe
Primary Hypercholesterolemia
Panitumumab
Metastatic Colorectal Cancer
Romozosumab
Postmenopausal Osteoporosis
Metoprolol
Cardiovascular Disease
Cinacalcet
End Stage Renal Disease
Inotuzumab Ozogamicin+Standard Maintenance Therapy
Leukemia, Acute Lymphoblastic
Omitted Doxorubicin
Leukemia, Acute Lymphoblastic
Cystagon® (Cysteamine Bitartrate)
Cystinosis
Levitra (Vardenafil, BAY38-9456)
Erectile Dysfunction
New Formulation Etanercept
Arthritis, Rheumatoid; Arthritis, Psoriatic
Nitroglycerin
Cardiovascular Disease
Buphenyl (NaPBA)
Urea Cycle Disorders
Evolocumab
Hyperlipidemia
Rosuvastatin
Hyperlipidemia
Predniso(lo)ne
Primary Immune Thrombocytopenia
Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
Breast Cancer
Evolocumab AI/pen
Primary Hypercholesterolemia
MR prednisone
Rheumatoid Arthritis
darbepoetin alfa SF
Kidney Disease
FOLFIRI Regimen
Metastatic Colorectal Cancer
HZT-501
Osteoarthritis
Epoetin alfa DT
Chronic Kidney Disease
Melphalan
Multiple Myeloma
6-tioguanine+Standard Maintenance Therapy
Leukemia, Acute Lymphoblastic
Romosozumab
Postmenopausal Women With Osteoporosis
Avacopan
Vasculitis
Sorafenib (Nexavar, BAY43-9006)
Thyroid Neoplasms
Lurbinectedin
Small Cell Lung Cancer (SCLC)
Cysteamine Bitartrate Delayed-release Capsules (RP103)
Cystinosis
Darbepoetin alpha (Aranesp)
Hematological Malignancies
ABP 798
Arthritis, Rheumatoid
ARM 1
Recurrent and/or Metastatic Head and Neck Cancer
Trifluridine and Tipiracil
Colorectal Cancer (CRC)
ABP 980
Breast Cancer
Rocatinlimab
Asthma
Denosumab (CP4)
Postmenopausal Osteoporosis
chemotherapy with LMWH - enoxaparin
Pancreatic Cancer
ABP 215
Non-small Cell Lung Cancer Metastatic
Talimogene laherparepvec
Melanoma
Apremilast (CC-10004)
Behcet Syndrome
Topical Therapy
Plaque Psoriasis
Vincrisitne
Leukemia, Acute Lymphoblastic
Lanadelumab
COVID-19
FOLFOX regimen
Metastatic Colorectal Cancer
RP103
Cystinosis
Blinatumomab
Acute Lymphoblastic Leukemia
AMG 073
Secondary Hyperparathyroidism
Aranesp®
Kidney Disease
rHuEPO
Cancer
Evolocumab AMD
Primary Hypercholesterolemia
Etanercept Liquid
Rheumatoid Arthritis
Romosozumab Prefilled Syringe
Bone Density, Low
MP-376 (Levofloxacin Solution for Inhalation)
Cystic Fibrosis
Risendronate
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Epoetin alfa RB
Nephrology
Iron saccharate (Venofer)
Hematological Malignancies
Actonel®
Osteoporosis
De Novo Administration of Darbepoetin Alfa
Chronic Kidney Disease
Background Statin Therapy
Dyslipidemia
ABP 938
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Ivabradine
Postural Orthostatic Tachycardia Syndrome
Oral methotrexate
Rheumatoid Arthritis
Dexamthasone
Acute Lymphoblastic Leukemia
Tezepelumab (AI)
Asthma
Ganitumab
Advanced Solid Tumors
pegsunercept
Rheumatoid Arthritis
tacrolimus (standard GVHD prophylaxis)
Graft Versus Host Disease
R-CHOEP14x6+HD-AraC+HD-Mtx
Diffuse Large B-Cell Lymphoma
Panitumumab + paclitaxel
Head and Neck Cancer
Panitumumab and CPT-11
Metastatic Colorectal Cancer
AGM 719
Rheumatoid Arthritis
MEDI9929
Atopic Dermatitis
Amgen 386
Glioblastoma Multiforme
Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta
Unresectable Locally Advanced NSCLC
Inotuzumab
Acute Lymphoblastic Leukemia
Subcutaneous Blinatumomab
CD19 Positive
Talimogene Laherparepvec (T-VEC)
Sarcoma
Carfilzomib & Non-IMiD Regimen
Multiple Myeloma
Panitumumab + FOLFOX (no-DP)
Metastatic Colorectal Cancer
Bleomycin sulfate
Sarcoma, Kaposi
Oral Contraceptive Pills (OCPs)
Amenorrhea
Erenumab-aooe (EREN) s.c. administered every four weeks for a total of five treatments
Temporomandibular Disorder
Vinblastine sulfate
HIV Infections
PEG asparaginase
Lymphoblastic Leukemia
bemarituzumab, trifluridine/tipiracil
Metastatic Gastro-esophageal Adenocarcinoma
AMG 102 and erlotinib
Carcinoma, Non-Small-Cell Lung
Anvumetostat
Advanced MTAP-null Solid Tumors
bemarituzumab, irinotecan
Metastatic Gastro-esophageal Adenocarcinoma
Panitumumab + FOLFOX (DP)
Metastatic Colorectal Cancer
Carfilzomib + Ibrutinib
Waldenstrom Macroglobulinemia
CC10004
Psoriasis
Filgrastim-SD/01
Non-small Cell Lung Cancer
Mitozantrone
Non-Hodgkin's Lymphoma
Alendronate Effervescent Oral Tablet
Erosive Osteoarthritis
Pegfilgrastim (Neulasta)
Multiple Myeloma
Intervention A: Irinotecan; Oxaliplatin; Neulasta
Non-Small Cell Lung Cancer
Adecatumumab
Liver Metastases
AMG 531 (Romiplostim)
MDS
IV Bisphosphonates
Breast Cancer
AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)
Breast Cancer
panitumumab, mytomicin C, 5-FU, radiation
Anal Squamous Cell Carcinoma
docetaxel + cyclophosphamide + pegfilgrastim
Female Breast Cancer
Rituximab + ACVBP regimen plus Pegfilgrastim
Untreated CD20-positive Large B-cell Lymphoma
Darbepoetin alfa SC
Anemia
T-VEC
Melanoma Stage III
5-Fluorouracil
Colorectal Cancer
Panitumumab (ABX-EGF)
Advanced Renal Cell Carcinoma
AMG 853
Asthma
epratuzumab
Non-Hodgkin's Lymphoma
cinacalcet (AMG 073)
Secondary Hyperparathyroidism
Antizol
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
N-Plate/romiplostim
Myelodysplastic Syndromes
VIB7734
Lupus Erythematosus, Systemic
Modified FOLFOX6
Advanced Solid Tumors
AMG 827
Asthma
IV Bisphosphonate q 4 weeks
Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Pegsunercept (PEG sTNF-RI)
Rheumatoid Arthritis
MP-376
Cystic Fibrosis (CF)
Teriparatide
Low Bone Mineral Density
CCX354-C
Rheumatoid Arthritis
CCX140-B
Diabetic Nephropathy
Autologous Stem Cell Transplant (ASCT)
Multiple Myeloma
AMG 655
Metastatic Colorectal Cancer
BUPHENYL®
Urea Cycle Disorders
CCX-354-C
Rheumatoid Arthritis
Tarlatamab treatment
DLL3-expressing Tumors
Carfilzomib for Inj 60 milligram (MG)
Multiple Myeloma in Relapse
Pre-emptive Skin Treatment
Metastatic Colorectal Cancer
AMG 479
Neuroendocrine Tumor
MTX/ARA-C
B-cell Acute Lymphoblastic Leukemia
ABX-EGF
Non-small Cell Lung Cancer
VIB4920
Sjögren's Syndrome
Belatacept
Allografts
Conatumumab
Colon Cancer
AMG 714
Psoriasis
AMG 719
Rheumatoid Arthritis
AMG 732
Thyroid Eye Disease
Abrilumab
Ulcerative Colitis
Brodalumab
Rheumatoid Arthritis
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
Anemia
Tezepelumab Dose 1
Chronic Spontaneous Urticaria
Cysteamine Bitartrate
Inherited Mitochondrial Disease, Including Leigh Syndrome
Recombinant Human Erythropoietin
Breast Cancer
CCX168
Vasculitis
ABX-EGF (panitumumab)
Metastatic Colorectal Cancer
IDE397
MTAP-null Non-Small-Cell Lung Cancer
recombinant human erythropoietin (rHuEPO)
Gynecological Malignancies
AMG 951 (rhApo2L/TRAIL)
Non-Small Cell Lung Cancer
HZN-1116
Sjogren's Syndrome
AMG 193
MTAP-deleted NSCLC
Systemic AMG 108
Osteoarthritis
Blinatumomab (MT103)
Acute Lymphoblastic Leukemia
anakinra
Rheumatoid Arthritis
AMG 317
Asthma
Liatermin
Parkinson's Disease
Daxdilimab
Alopecia Areata
AMG 151
Diabetes Mellitus
Intra-articular metHuIL-1ra (anakinra)
Osteoarthritis
IV iron dextran
Anemia
Neulasta
Breast Cancer
CC-11050
Cutaneous Lupus Erythematosus
Erenumab PFS
Migraine
CCX 354-C
Rheumatoid Arthritis
AMG 706
Gastrointestinal Cancer
AMG 337
Stomach Neoplasms
6-Mercaptopurine
Acute Lymphoblastic Leukemia
Naproxen
Bone Pain in Stage I - III Breast Cancer
CC-10004
Psoriasis
Oprozomib
Multiple Myeloma
Previous denosumab
Low Bone Mass
Sensipar (Cinacalcet HCl)
Secondary Hyperparathyroidism
Calaspargase
Acute Lymphoblastic Leukemia
AMG 301
Chronic Migraine or Episodic Migraine
AMG 108
Rheumatoid Arthritis
Lodotra
Asthma
CCX282-B
Crohn's Disease
AMG 223
End Stage Renal Disease
Reactive Skin Treatment
Metastatic Colorectal Cancer
NaPBA
Urea Cycle Disorders
Motesanib diphosphate
Lung Cancer
AMG 102
Cancer
RCHOP
Richter Syndrome
Romidepsin
Peripheral T Cell Lymphoma
Epirubicin, Cisplatin, Capecitabine, Panitumumab
Stomach Neoplasms
RAD
Multiple Myeloma
Interferon gamma-1b
Acute Myeloid Leukemia
AMG 334
Post-Traumatic Headache
CPT-11
Non Small Cell Lung Cancer
Denosumab Prefilled Syringe
Premenopausal Idiopathic Osteoporosis
liposomal cytarabine
Primary Disease
5FU
Squamous Cell Carcinoma of Head and Neck
CEEP regimen
Lymphoma
Mini-CVD
B-cell Acute Lymphoblastic Leukemia
standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine
Acute Myeloid Leukemia
Consolidation with 4 cycles of CarCyDex
Multiple Myeloma
TALIMOGENE LAHERPAREPVEC (TVEC)
Melanoma
Adecatumumab and FOLFOX
Liver Metastases
Intervention B: Etoposide; Carboplatin; Neulasta
Non-Small Cell Lung Cancer
Donor Leukocyte Infusion (DLI)
Acute Myeloid Leukemia
Erenumab AI/Pen
Migraine
Myocet
Breast Cancer
Aranesp
Prostate Cancer
FOLFOXIRI + Panitumumab
Metastatic Colorectal Cancer
Panitumumab+irinotecan
Metastatic Colorectal Cancer
Denosumab/Subcutaneous
Multiple Myeloma
Maintenance Chemotherapy
Metastatic Colorectal Cancer
5Fluorouracil
Rectal Cancer
epirubicin hydrochloride
Breast Cancer
Randomization to No Panitumumab
Metastatic Colorectal Cancer
Trebananib
Advanced Renal Cell Carcinoma
Doxycycline
Skin Toxicity
TVEC into target lesions - week 1-2
Squamous Cell Carcinoma
leucovorin calcium
Mucinous Adenocarcinoma of the Colon
r-metHuLeptin
HAART-induced Lipodystrophy and Metabolic Syndrome
AMG 557/MEDI5872
Primary Sjögren's Syndrome
Doxorubicin hydrochloride (liposomal)
Sarcoma, Kaposi
Dapagliflozin Tab
HFrEF
Acyclovir
Metastatic Castration-resistant Prostate Cancer
Denosumab Q4W
Multiple Myeloma
bemarituzumab, paclitaxel, ramucirumab
Metastatic Gastro-esophageal Adenocarcinoma
TVEC into target lesions 3wks after 1st injection
Squamous Cell Carcinoma
TVEC into target lesions 2wks after 2nd injection
Squamous Cell Carcinoma
KRdD followed by auto-HCT
Multiple Myeloma
TVEC into target lesions 2wks after 3rd injection
Squamous Cell Carcinoma
Carfilzomib & IMiD containing regimen
Multiple Myeloma
KRdD only
Multiple Myeloma
Rozibafusp Alfa
Systemic Lupus Erythematosus (SLE)
Diphenhydramine
Multiple Myeloma
AMG 509
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lumakras Sotorasib | Approved | KRAS G12C NSCLC | Fast TrackBreakthrough | Patent 2040 |
Cystagon® | Phase 3 | Cystinosis | - | - |
darbepoetin alfa | Phase 3 | Anemia | - | - |
Denosumab (AMG 162) | Phase 3 | Postmenopausal Osteoporosis | - | - |
mFOLFOX6 | Phase 3 | Gastric Cancer | - | - |
Zoledronic Acid | Phase 3 | Bone Metastases | - | - |
Denosumab | Phase 3 | Osteoporosis | - | - |
ARM 2 | Phase 3 | Recurrent and/or Metastatic Head and Neck Cancer | - | - |
Denosumab (CP2) | Phase 3 | Postmenopausal Osteoporosis | - | - |
Ustekinumab | Phase 3 | Psoriasis | - | - |
Topical treatments or phototherapy | Phase 3 | Plaque Psoriasis | - | - |
Standard Chemotherapy | Phase 3 | Cancer | - | - |
Oxaliplatin Based Chemotherapy | Phase 3 | Colorectal Cancer | - | - |
etanercept pre-filled syringe subcutaneous injection | Phase 3 | Rheumatoid Arthritis | - | - |
Chemotherapy | Phase 3 | Gastric Cancer | - | - |
Teprotumumab | Phase 3 | Thyroid Eye Disease | - | - |
1=Etanercept | Phase 3 | Psoriasis | - | - |
Tarlatamab | Phase 3 | Small Cell Lung Cancer | OrphanFast TrackBreakthrough | |
Non-steroidal aromatase inhibitor therapy | Phase 3 | Breast Cancer | - | - |
Recombinant Human Keratinocyte Growth Factor | Phase 3 | Stomatitis | - | - |
Pegloticase | Phase 3 | Uncontrolled Gout | - | - |
Ibuprofen/famotidine | Phase 3 | Ulcer | - | - |
interferon γ-1b | Phase 3 | Friedreich's Ataxia | - | - |
Anakinra (Kineret®) | Phase 3 | Rheumatoid Arthritis | - | - |
Ocrelizumab (US) | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | - | - |
Aranesp® (darbepoetin alfa) | Phase 3 | Kidney Disease | - | - |
Ibandronate | Phase 3 | Postmenopausal Osteoporosis | - | - |
ABP 710 | Phase 3 | Arthritis, Rheumatoid | - | - |
Sotorasib | Phase 3 | Non-small Cell Lung Cancer | - | - |
AMG 386 | Phase 3 | Ovarian Cancer | - | - |
AMG 510 | Phase 3 | KRAS p, G12c Mutated /Advanced Metastatic NSCLC | - | - |
Statin therapy | Phase 3 | Coronary Artery Disease (CAD) | - | - |
Xaluritamig | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
Darbepoetin alpha | Phase 3 | Myelodysplastic Syndrome | - | - |
filgrastim | Phase 3 | Sarcoma | - | - |
Erenumab Dose 1 | Phase 3 | Migraine | - | - |
Etanercept/Autoinjector A | Phase 3 | Rheumatoid Arthritis | - | - |
Cytarabine | Phase 3 | Lymphoma | - | - |
TAC | Phase 3 | Breast Cancer | - | - |
Pegaspargase | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
ABP 654 | Phase 3 | Plaque Psoriasis | - | - |
Erenumab Dose 2 | Phase 3 | Migraine | - | - |
Denosumab (for the open-label treatment phase) | Phase 3 | Cancer | - | - |
pegfilgrastim | Phase 3 | Breast Cancer | - | - |
Inebilizumab | Phase 3 | IgG4 Related Disease | - | - |
Dazodalibep | Phase 3 | Sjögren's Syndrome (SS) | - | - |
Topical agents | Phase 3 | Psoriasis | - | - |
AMG 162 | Phase 3 | Postmenopausal Osteoporosis | - | - |
Cinacalcet HCl | Phase 3 | Kidney Disease | - | - |
ABP 234 | Phase 3 | Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | - | - |
HPN-100 | Phase 3 | Cirrhosis | - | - |
ABP 501 | Phase 3 | Arthritis, Rheumatoid | - | - |
Low-intensity chemotherapy regimen | Phase 3 | Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) | - | - |
Palifermin | Phase 3 | Head and Neck Cancer | - | - |
romosozumab HCP administration with PFS | Phase 3 | Post-Menopausal Osteoporosis | - | - |
Olpasiran | Phase 3 | Cardiovascular Disease | - | - |
Cysteamine Bitartrate Delayed-release Capsules | Phase 3 | Cystinosis | - | - |
Romiplostim | Phase 3 | Chemotherapy-induced Thrombocytopenia | - | - |
Darbepoetin alfa and Epoetin alfa | Phase 3 | Anemia | - | - |
AMG 531 | Phase 3 | Thrombocytopenia | - | - |
Omitted Vincristine+Dexamethasone pulses | Phase 3 | Leukemia, Acute Lymphoblastic | - | - |
AMG 162/Denosumab | Phase 3 | Breast Cancer | - | - |
Bemarituzumab | Phase 3 | Gastric Cancer | - | - |
Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
alendronate | Phase 3 | Osteoporosis | - | - |
Erenumab | Phase 3 | Migraine | - | - |
Maridebart cafraglutide | Phase 3 | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | - | - |
ABP 206 | Phase 3 | Melanoma | - | - |
Irinotecan Based Chemotherapy | Phase 3 | Colorectal Cancer | - | - |
ABP 692 | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | - | - |
Alendronate Tab | Phase 3 | Bone Density | - | - |
Erenumab Dose 3 | Phase 3 | Migraine | - | - |
Atorvastatin | Phase 3 | Hyperlipidemia | - | - |
Carfilzomib | Phase 3 | Multiple Myeloma | - | - |
Aeroquin | Phase 3 | Cystic Fibrosis | - | - |
Omnipaque | Phase 3 | Cardiovascular Disease | - | - |
Commercial Formulation Etanercept | Phase 3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | - | - |
ABP 959 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Apremilast | Phase 3 | Behçet's Disease | - | - |
Etelcalcetide | Phase 3 | Secondary Hyperparathyroidism | - | - |
Bisphosphonate | Phase 3 | Osteogenesis Imperfecta | - | - |
Ezetimibe | Phase 3 | Hyperlipidemia | - | - |
Evolocumab Pre-filled Syringe | Phase 3 | Primary Hypercholesterolemia | - | - |
Panitumumab | Phase 3 | Metastatic Colorectal Cancer | - | - |
Romozosumab | Phase 3 | Postmenopausal Osteoporosis | - | - |
Metoprolol | Phase 3 | Cardiovascular Disease | - | - |
Cinacalcet | Phase 3 | End Stage Renal Disease | - | - |
Inotuzumab Ozogamicin+Standard Maintenance Therapy | Phase 3 | Leukemia, Acute Lymphoblastic | - | - |
Omitted Doxorubicin | Phase 3 | Leukemia, Acute Lymphoblastic | - | - |
Cystagon® (Cysteamine Bitartrate) | Phase 3 | Cystinosis | - | - |
Levitra (Vardenafil, BAY38-9456) | Phase 3 | Erectile Dysfunction | - | - |
New Formulation Etanercept | Phase 3 | Arthritis, Rheumatoid; Arthritis, Psoriatic | - | - |
Nitroglycerin | Phase 3 | Cardiovascular Disease | - | - |
Buphenyl (NaPBA) | Phase 3 | Urea Cycle Disorders | - | - |
Evolocumab | Phase 3 | Hyperlipidemia | - | - |
Rosuvastatin | Phase 3 | Hyperlipidemia | - | - |
Predniso(lo)ne | Phase 3 | Primary Immune Thrombocytopenia | - | - |
Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa | Phase 3 | Breast Cancer | - | - |
Evolocumab AI/pen | Phase 3 | Primary Hypercholesterolemia | - | - |
MR prednisone | Phase 3 | Rheumatoid Arthritis | - | - |
darbepoetin alfa SF | Phase 3 | Kidney Disease | - | - |
FOLFIRI Regimen | Phase 3 | Metastatic Colorectal Cancer | - | - |
HZT-501 | Phase 3 | Osteoarthritis | - | - |
Epoetin alfa DT | Phase 3 | Chronic Kidney Disease | - | - |
Melphalan | Phase 3 | Multiple Myeloma | - | - |
6-tioguanine+Standard Maintenance Therapy | Phase 3 | Leukemia, Acute Lymphoblastic | - | - |
Romosozumab | Phase 3 | Postmenopausal Women With Osteoporosis | - | - |
Avacopan | Phase 3 | Vasculitis | - | - |
Sorafenib (Nexavar, BAY43-9006) | Phase 3 | Thyroid Neoplasms | - | - |
Lurbinectedin | Phase 3 | Small Cell Lung Cancer (SCLC) | - | - |
Cysteamine Bitartrate Delayed-release Capsules (RP103) | Phase 3 | Cystinosis | - | - |
Darbepoetin alpha (Aranesp) | Phase 3 | Hematological Malignancies | - | - |
ABP 798 | Phase 3 | Arthritis, Rheumatoid | - | - |
ARM 1 | Phase 3 | Recurrent and/or Metastatic Head and Neck Cancer | - | - |
Trifluridine and Tipiracil | Phase 3 | Colorectal Cancer (CRC) | - | - |
ABP 980 | Phase 3 | Breast Cancer | - | - |
Rocatinlimab | Phase 3 | Asthma | - | - |
Denosumab (CP4) | Phase 3 | Postmenopausal Osteoporosis | - | - |
chemotherapy with LMWH - enoxaparin | Phase 3 | Pancreatic Cancer | - | - |
ABP 215 | Phase 3 | Non-small Cell Lung Cancer Metastatic | - | - |
Talimogene laherparepvec | Phase 3 | Melanoma | - | - |
Apremilast (CC-10004) | Phase 3 | Behcet Syndrome | - | - |
Topical Therapy | Phase 3 | Plaque Psoriasis | - | - |
Vincrisitne | Phase 3 | Leukemia, Acute Lymphoblastic | - | - |
Lanadelumab | Phase 3 | COVID-19 | - | - |
FOLFOX regimen | Phase 3 | Metastatic Colorectal Cancer | - | - |
RP103 | Phase 3 | Cystinosis | - | - |
Blinatumomab | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
AMG 073 | Phase 3 | Secondary Hyperparathyroidism | - | - |
Aranesp® | Phase 3 | Kidney Disease | - | - |
rHuEPO | Phase 3 | Cancer | - | - |
Evolocumab AMD | Phase 3 | Primary Hypercholesterolemia | - | - |
Etanercept Liquid | Phase 3 | Rheumatoid Arthritis | - | - |
Romosozumab Prefilled Syringe | Phase 3 | Bone Density, Low | - | - |
MP-376 (Levofloxacin Solution for Inhalation) | Phase 3 | Cystic Fibrosis | - | - |
Risendronate | Phase 3 | Steroid-induced Osteopor, Glucocorticoid-induced Ostepor | - | - |
Epoetin alfa RB | Phase 3 | Nephrology | - | - |
Iron saccharate (Venofer) | Phase 3 | Hematological Malignancies | - | - |
Actonel® | Phase 3 | Osteoporosis | - | - |
De Novo Administration of Darbepoetin Alfa | Phase 3 | Chronic Kidney Disease | - | - |
Background Statin Therapy | Phase 3 | Dyslipidemia | - | - |
ABP 938 | Phase 3 | Neovascular (Wet) Age-related Macular Degeneration (AMD) | - | - |
Ivabradine | Phase 3 | Postural Orthostatic Tachycardia Syndrome | - | - |
Oral methotrexate | Phase 3 | Rheumatoid Arthritis | - | - |
Dexamthasone | Phase 3 | Acute Lymphoblastic Leukemia | - | - |
Tezepelumab (AI) | Phase 3 | Asthma | - | - |
Ganitumab | Phase 2 | Advanced Solid Tumors | - | - |
pegsunercept | Phase 2 | Rheumatoid Arthritis | - | - |
tacrolimus (standard GVHD prophylaxis) | Phase 2 | Graft Versus Host Disease | - | - |
R-CHOEP14x6+HD-AraC+HD-Mtx | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
Panitumumab + paclitaxel | Phase 2 | Head and Neck Cancer | - | - |
Panitumumab and CPT-11 | Phase 2 | Metastatic Colorectal Cancer | - | - |
AGM 719 | Phase 2 | Rheumatoid Arthritis | - | - |
MEDI9929 | Phase 2 | Atopic Dermatitis | - | - |
Amgen 386 | Phase 2 | Glioblastoma Multiforme | - | - |
Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta | Phase 2 | Unresectable Locally Advanced NSCLC | - | - |
Inotuzumab | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
Subcutaneous Blinatumomab | Phase 2 | CD19 Positive | - | - |
Talimogene Laherparepvec (T-VEC) | Phase 2 | Sarcoma | - | - |
Carfilzomib & Non-IMiD Regimen | Phase 2 | Multiple Myeloma | - | - |
Panitumumab + FOLFOX (no-DP) | Phase 2 | Metastatic Colorectal Cancer | - | - |
Bleomycin sulfate | Phase 2 | Sarcoma, Kaposi | - | - |
Oral Contraceptive Pills (OCPs) | Phase 2 | Amenorrhea | - | - |
Erenumab-aooe (EREN) s.c. administered every four weeks for a total of five treatments | Phase 2 | Temporomandibular Disorder | - | - |
Vinblastine sulfate | Phase 2 | HIV Infections | - | - |
PEG asparaginase | Phase 2 | Lymphoblastic Leukemia | - | - |
bemarituzumab, trifluridine/tipiracil | Phase 2 | Metastatic Gastro-esophageal Adenocarcinoma | - | - |
AMG 102 and erlotinib | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Anvumetostat | Phase 2 | Advanced MTAP-null Solid Tumors | - | - |
bemarituzumab, irinotecan | Phase 2 | Metastatic Gastro-esophageal Adenocarcinoma | - | - |
Panitumumab + FOLFOX (DP) | Phase 2 | Metastatic Colorectal Cancer | - | - |
Carfilzomib + Ibrutinib | Phase 2 | Waldenstrom Macroglobulinemia | - | - |
CC10004 | Phase 2 | Psoriasis | - | - |
Filgrastim-SD/01 | Phase 2 | Non-small Cell Lung Cancer | - | - |
Mitozantrone | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Alendronate Effervescent Oral Tablet | Phase 2 | Erosive Osteoarthritis | - | - |
Pegfilgrastim (Neulasta) | Phase 2 | Multiple Myeloma | - | - |
Intervention A: Irinotecan; Oxaliplatin; Neulasta | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Adecatumumab | Phase 2 | Liver Metastases | - | - |
AMG 531 (Romiplostim) | Phase 2 | MDS | - | - |
IV Bisphosphonates | Phase 2 | Breast Cancer | - | - |
AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P) | Phase 2 | Breast Cancer | - | - |
panitumumab, mytomicin C, 5-FU, radiation | Phase 2 | Anal Squamous Cell Carcinoma | - | - |
docetaxel + cyclophosphamide + pegfilgrastim | Phase 2 | Female Breast Cancer | - | - |
Rituximab + ACVBP regimen plus Pegfilgrastim | Phase 2 | Untreated CD20-positive Large B-cell Lymphoma | - | - |
Darbepoetin alfa SC | Phase 2 | Anemia | - | - |
T-VEC | Phase 2 | Melanoma Stage III | - | - |
5-Fluorouracil | Phase 2 | Colorectal Cancer | - | - |
Panitumumab (ABX-EGF) | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
AMG 853 | Phase 2 | Asthma | - | - |
epratuzumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
cinacalcet (AMG 073) | Phase 2 | Secondary Hyperparathyroidism | - | - |
Antizol | Phase 2 | Aldehyde Dehydrogenase-2 (ALDH2) Deficiency | - | - |
N-Plate/romiplostim | Phase 2 | Myelodysplastic Syndromes | - | - |
VIB7734 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
Modified FOLFOX6 | Phase 2 | Advanced Solid Tumors | - | - |
AMG 827 | Phase 2 | Asthma | - | - |
IV Bisphosphonate q 4 weeks | Phase 2 | Bone Metastases in Men With Hormone-Refractory Prostate Cancer | - | - |
Pegsunercept (PEG sTNF-RI) | Phase 2 | Rheumatoid Arthritis | - | - |
MP-376 | Phase 2 | Cystic Fibrosis (CF) | - | - |
Teriparatide | Phase 2 | Low Bone Mineral Density | - | - |
CCX354-C | Phase 2 | Rheumatoid Arthritis | - | - |
CCX140-B | Phase 2 | Diabetic Nephropathy | - | - |
Autologous Stem Cell Transplant (ASCT) | Phase 2 | Multiple Myeloma | - | - |
AMG 655 | Phase 2 | Metastatic Colorectal Cancer | - | - |
BUPHENYL® | Phase 2 | Urea Cycle Disorders | - | - |
CCX-354-C | Phase 2 | Rheumatoid Arthritis | - | - |
Tarlatamab treatment | Phase 2 | DLL3-expressing Tumors | - | - |
Carfilzomib for Inj 60 milligram (MG) | Phase 2 | Multiple Myeloma in Relapse | - | - |
Pre-emptive Skin Treatment | Phase 2 | Metastatic Colorectal Cancer | - | - |
AMG 479 | Phase 2 | Neuroendocrine Tumor | - | - |
MTX/ARA-C | Phase 2 | B-cell Acute Lymphoblastic Leukemia | - | - |
ABX-EGF | Phase 2 | Non-small Cell Lung Cancer | - | - |
VIB4920 | Phase 2 | Sjögren's Syndrome | - | - |
Belatacept | Phase 2 | Allografts | - | - |
Conatumumab | Phase 2 | Colon Cancer | - | - |
AMG 714 | Phase 2 | Psoriasis | - | - |
AMG 719 | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 732 | Phase 2 | Thyroid Eye Disease | - | - |
Abrilumab | Phase 2 | Ulcerative Colitis | - | - |
Brodalumab | Phase 2 | Rheumatoid Arthritis | - | - |
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa) | Phase 2 | Anemia | - | - |
Tezepelumab Dose 1 | Phase 2 | Chronic Spontaneous Urticaria | - | - |
Cysteamine Bitartrate | Phase 2 | Inherited Mitochondrial Disease, Including Leigh Syndrome | - | - |
Recombinant Human Erythropoietin | Phase 2 | Breast Cancer | - | - |
CCX168 | Phase 2 | Vasculitis | - | - |
ABX-EGF (panitumumab) | Phase 2 | Metastatic Colorectal Cancer | - | - |
IDE397 | Phase 2 | MTAP-null Non-Small-Cell Lung Cancer | - | - |
recombinant human erythropoietin (rHuEPO) | Phase 2 | Gynecological Malignancies | - | - |
AMG 951 (rhApo2L/TRAIL) | Phase 2 | Non-Small Cell Lung Cancer | - | - |
HZN-1116 | Phase 2 | Sjogren's Syndrome | - | - |
AMG 193 | Phase 2 | MTAP-deleted NSCLC | - | - |
Systemic AMG 108 | Phase 2 | Osteoarthritis | - | - |
Blinatumomab (MT103) | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
anakinra | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 317 | Phase 2 | Asthma | - | - |
Liatermin | Phase 2 | Parkinson's Disease | - | - |
Daxdilimab | Phase 2 | Alopecia Areata | - | - |
AMG 151 | Phase 2 | Diabetes Mellitus | - | - |
Intra-articular metHuIL-1ra (anakinra) | Phase 2 | Osteoarthritis | - | - |
IV iron dextran | Phase 2 | Anemia | - | - |
Neulasta | Phase 2 | Breast Cancer | - | - |
CC-11050 | Phase 2 | Cutaneous Lupus Erythematosus | - | - |
Erenumab PFS | Phase 2 | Migraine | - | - |
CCX 354-C | Phase 2 | Rheumatoid Arthritis | - | - |
AMG 706 | Phase 2 | Gastrointestinal Cancer | - | - |
AMG 337 | Phase 2 | Stomach Neoplasms | - | - |
6-Mercaptopurine | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
Naproxen | Phase 2 | Bone Pain in Stage I - III Breast Cancer | - | - |
CC-10004 | Phase 2 | Psoriasis | - | - |
Oprozomib | Phase 2 | Multiple Myeloma | - | - |
Previous denosumab | Phase 2 | Low Bone Mass | - | - |
Sensipar (Cinacalcet HCl) | Phase 2 | Secondary Hyperparathyroidism | - | - |
Calaspargase | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
AMG 301 | Phase 2 | Chronic Migraine or Episodic Migraine | - | - |
AMG 108 | Phase 2 | Rheumatoid Arthritis | - | - |
Lodotra | Phase 2 | Asthma | - | - |
CCX282-B | Phase 2 | Crohn's Disease | - | - |
AMG 223 | Phase 2 | End Stage Renal Disease | - | - |
Reactive Skin Treatment | Phase 2 | Metastatic Colorectal Cancer | - | - |
NaPBA | Phase 2 | Urea Cycle Disorders | - | - |
Motesanib diphosphate | Phase 2 | Lung Cancer | - | - |
AMG 102 | Phase 2 | Cancer | - | - |
RCHOP | Phase 2 | Richter Syndrome | - | - |
Romidepsin | Phase 2 | Peripheral T Cell Lymphoma | - | - |
Epirubicin, Cisplatin, Capecitabine, Panitumumab | Phase 2 | Stomach Neoplasms | - | - |
RAD | Phase 2 | Multiple Myeloma | - | - |
Interferon gamma-1b | Phase 2 | Acute Myeloid Leukemia | - | - |
AMG 334 | Phase 2 | Post-Traumatic Headache | - | - |
CPT-11 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Denosumab Prefilled Syringe | Phase 2 | Premenopausal Idiopathic Osteoporosis | - | - |
liposomal cytarabine | Phase 2 | Primary Disease | - | - |
5FU | Phase 2 | Squamous Cell Carcinoma of Head and Neck | - | - |
CEEP regimen | Phase 2 | Lymphoma | - | - |
Mini-CVD | Phase 2 | B-cell Acute Lymphoblastic Leukemia | - | - |
standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine | Phase 2 | Acute Myeloid Leukemia | - | - |
Consolidation with 4 cycles of CarCyDex | Phase 2 | Multiple Myeloma | - | - |
TALIMOGENE LAHERPAREPVEC (TVEC) | Phase 2 | Melanoma | - | - |
Adecatumumab and FOLFOX | Phase 2 | Liver Metastases | - | - |
Intervention B: Etoposide; Carboplatin; Neulasta | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Donor Leukocyte Infusion (DLI) | Phase 2 | Acute Myeloid Leukemia | - | - |
Erenumab AI/Pen | Phase 2 | Migraine | - | - |
Myocet | Phase 2 | Breast Cancer | - | - |
Aranesp | Phase 2 | Prostate Cancer | - | - |
FOLFOXIRI + Panitumumab | Phase 2 | Metastatic Colorectal Cancer | - | - |
Panitumumab+irinotecan | Phase 2 | Metastatic Colorectal Cancer | - | - |
Denosumab/Subcutaneous | Phase 2 | Multiple Myeloma | - | - |
Maintenance Chemotherapy | Phase 2 | Metastatic Colorectal Cancer | - | - |
5Fluorouracil | Phase 2 | Rectal Cancer | - | - |
epirubicin hydrochloride | Phase 2 | Breast Cancer | - | - |
Randomization to No Panitumumab | Phase 2 | Metastatic Colorectal Cancer | - | - |
Trebananib | Phase 2 | Advanced Renal Cell Carcinoma | - | - |
Doxycycline | Phase 2 | Skin Toxicity | - | - |
TVEC into target lesions - week 1-2 | Phase 2 | Squamous Cell Carcinoma | - | - |
leucovorin calcium | Phase 2 | Mucinous Adenocarcinoma of the Colon | - | - |
r-metHuLeptin | Phase 2 | HAART-induced Lipodystrophy and Metabolic Syndrome | - | - |
AMG 557/MEDI5872 | Phase 2 | Primary Sjögren's Syndrome | - | - |
Doxorubicin hydrochloride (liposomal) | Phase 2 | Sarcoma, Kaposi | - | - |
Dapagliflozin Tab | Phase 2 | HFrEF | - | - |
Acyclovir | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
Denosumab Q4W | Phase 2 | Multiple Myeloma | - | - |
bemarituzumab, paclitaxel, ramucirumab | Phase 2 | Metastatic Gastro-esophageal Adenocarcinoma | - | - |
TVEC into target lesions 3wks after 1st injection | Phase 2 | Squamous Cell Carcinoma | - | - |
TVEC into target lesions 2wks after 2nd injection | Phase 2 | Squamous Cell Carcinoma | - | - |
KRdD followed by auto-HCT | Phase 2 | Multiple Myeloma | - | - |
TVEC into target lesions 2wks after 3rd injection | Phase 2 | Squamous Cell Carcinoma | - | - |
Carfilzomib & IMiD containing regimen | Phase 2 | Multiple Myeloma | - | - |
KRdD only | Phase 2 | Multiple Myeloma | - | - |
Rozibafusp Alfa | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
Diphenhydramine | Phase 2 | Multiple Myeloma | - | - |
AMG 509 | Phase 1 | Prostate Cancer | Fast Track | - |
eosinophilic esophagitis
3 drugs in this indication
Temporomandibular Disorder
2 drugs in this indication
KRAS G12C NSCLC
1 drug in this indication
Small Cell Lung Cancer
1 drug in this indication
Prostate Cancer
1 drug in this indication
reduction of cardiovascular risk, prevention of first myocardial infarction or stroke
1 drug in this indication
Cardiovascular risk reduction, primary prevention of myocardial infarction and stroke
1 drug in this indication
eosinophilic esophagitis (EoE), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP)
1 drug in this indication
Reduction of risk of first myocardial infarction or stroke in patients with cardiovascular disease
1 drug in this indication
Systemic Lupus Erythematosus (SLE)
1 drug in this indication
primary prevention of myocardial infarction and stroke
1 drug in this indication
rare disease
1 drug in this indication
Reduction of risk of first myocardial infarction or stroke
1 drug in this indication
reduction of risk of first heart attack or stroke
1 drug in this indication
Obesity
1 drug in this indication
lung cancer
1 drug in this indication
Rheumatoid Arthritis
1 drug in this indication
oncology
1 drug in this indication
rare kidney disease
1 drug in this indication
ANCA-associated vasculitis (AAV)
1 drug in this indication
Asthma with swallowing disorder
1 drug in this indication
Extensive-stage small cell lung cancer (frontline maintenance)
1 drug in this indication
first-line maintenance treatment of small cell lung cancer
1 drug in this indication
First-line extensive stage small cell lung cancer (ES-SCLC)
1 drug in this indication
Extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Amgen Inc.'s drug pipeline?→
CatalystAlert tracks 311 drug candidates in Amgen Inc.'s (AMGN) pipeline across Phase 3, Phase 2, Phase 1, Approved. Its lead program is Lumakras (Approved). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Amgen Inc.'s next FDA catalyst?→
Amgen Inc.'s (AMGN) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AMGN biotech catalysts?→
Add AMGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Amgen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
